Precision NanoSystems NanoAssemblr™ platform has been selected for the controlled manufacture of nanomedicines as part of the multinational B-SMART (Brain-Specific, Modular and Active RNA Therapeutics ...

Precision NanoSystems empowers researchers to develop genetic medicines through its NanoAssmblr technology, helping companies solve drug delivery challenges in both cancer and infectious diseases.

VANCOUVER, June 7, 2018 /CNW/ - Precision NanoSystems (PNI) today announced that it has closed a US$6M Series B investment. The funds will be used to expand PNI's products and services globally and to ...

Precision NanoSystems has launched the NanoAssemblr™ Scale-Up system to support the clinical development of nanomedicines. This latest addition to the NanoAssemblr range is designed for the ...